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Abstract
Inherited disorders of hyperbilirubinemia may be caused by increased bilirubin production or
decreased bilirubin clearance. Reduced hepatic bilirubin clearance can be due to defective 1)
unconjugated bilirubin uptake and intrahepatic storage, 2) conjugation of glucuronic acid to
bilirubin (e.g. Gilbert syndrome, Crigler-Najjar syndrome, Lucey-Driscoll syndrome, breast milk
jaundice), 3) bilirubin excretion into bile (Dubin-Johnson syndrome), or 4) conjugated bilirubin reuptake (Rotor syndrome). In this review, the molecular mechanisms and clinical manifestations of
these conditions are described, as well as current approaches to diagnosis and therapy.

Author Manuscript

Introduction
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Bilirubin is the end product of heme catabolism and originates primarily from the
breakdown of erythrocyte hemoglobin in the reticuloendothelial system. A smaller, yet
significant proportion is derived from the breakdown of other heme proteins and ineffective
erythropoiesis in the bone marrow (1). Bilirubin is poorly soluble in water and when
circulating in blood, is mostly bound to serum albumin. Small amounts of unbound,
unconjugated bilirubin exist in equilibrium with bound, unconjugated bilirubin in the
circulation. This unbound, circulating bilirubin is neurotoxic and associated with acute
bilirubin encephalopathy, which can progress to the more permanent and devastating chronic
bilirubin encephalopathy, also known as kernicterus (2). Under normal conditions,
unconjugated bilirubin is rapidly and selectively taken up by hepatocytes, conjugated to
water-soluble bilirubin glucuronide conjugates, and ultimately secreted into bile.
Disorders that produce hyperbilirubinemia can be divided into those in which excessive
bilirubin is produced (hemolysis), those in which there is decreased clearance of bilirubin
(hepatic or intestinal), and combinations of the two. Newborns are particularly susceptible to
developing hyperbilirubinemia as they have increased bilirubin synthesis (secondary to
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elevated hemoglobin concentrations and shorter red blood cell lifespan) and inefficient
hepatic uptake, conjugation, and excretion of bilirubin. The aim of this review is to describe
hepatic clearance of bilirubin and focus on inherited disorders of hepatic uptake,
conjugation, and excretion of bilirubin.

Bilirubin Clearance by the Liver
There are four major steps in hepatic clearance of bilirubin: 1) uptake and storage of
unconjugated bilirubin by hepatocytes, 2) conjugation of bilirubin to bilirubin glucuronides,
3) excretion of conjugated bilirubin into bile, and 4) reuptake of conjugated bilirubin by
hepatocytes.
Uptake and Intrahepatic Storage
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Bilirubin dissociates from albumin before entering hepatocytes. It is not clear whether the
initial uptake of free bilirubin is carrier-mediated or by passive diffusion (3). Recent studies
have described a role for membrane-associated organic anion transport proteins (OATPs) in
bilirubin uptake by hepatocytes. OATPs belong to the OATP superfamily, which is also
known as the solute carrier organic anion transporter (SLCO) superfamily (4). Bilirubin is a
known substrate for the human SLCO1B1/OATP1B1 and SLCO1B3/OATP1B3 proteins (5),
but most studies have shown that it is conjugated (as opposed to unconjugated) bilirubin that
is the major substrate for these transporters (5,6). OATPs therefore play an important role in
the reuptake of conjugated bilirubin (see Secretion into Plasma and Reuptake and Rotor
Syndrome). However, there is evidence from genome-wide association studies that
polymorphisms resulting in decreased SLCO1B1/OATP1B1 or SLCO1B3/OATP1B3
activity are associated with higher serum levels of both conjugated and unconjugated
bilirubin (7,8), suggesting a role for OATPs in the initial uptake of unconjugated bilirubin
into hepatocytes as well.
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Once inside the hepatocyte, bilirubin binds to the cytoplasmic transport protein ligandin,
which belongs to the glutathione-S-transferases (GST) family. Ligandin has a much higher
affinity for bilirubin than albumin, and therefore facilitates intrahepatocyte bilirubin
accumulation and storage (9).
Conjugation
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After binding to ligandin, bilirubin is transported to the smooth endoplasmic reticulum, the
site at which the conjugating enzyme, uridine diphosphate glucuronosyl transferase 1A1
(UGT1A1) is localized. UGT1A1 is a transmembrane protein that has a binding site for
bilirubin and another one for uridine diphosphate glucuronic acid. Conjugation is a two-step
process; in the first step, the UGT1A1 enzyme catalyzes the transfer of one glucuronic acid
molecule to one of the carboxyl groups on bilirubin forming bilirubin monoglucuronide.
Addition of another molecule of glucuronic acid to the second carboxyl group forms
bilirubin diglucuronide. Both bilirubin mono- and diglucuronide are water-soluble and can
readily be excreted in bile.
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Once bilirubin glucuronide leaves the endoplasmic reticulum and is transported into the
cytoplasm, it can diffuse toward either the apical surface of the hepatocyte (canalicular
surface) or the basolateral surface (sinusoidal surface). At the canalicular surface, it is
efficiently secreted into bile via ATP-binding cassette (ABC) transporters. The predominant
ABC transporter responsible for bilirubin excretion is the multidrug resistance-associated
protein ABCC2/MRP2 transporter (10). Recently, another ABC transporter, the breast
cancer resistance protein ABCG2/BCRP has also been identified to play a role in bilirubin
excretion, albeit to a lesser degree (11).
Secretion into Plasma and Reuptake
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Interestingly, a substantial fraction of bilirubin glucuronide is secreted back into sinusoidal
blood and subsequently taken up again by the hepatocytes for biliary excretion. The process
of conjugated bilirubin excretion at the basolateral surface is mediated by the transporter
ABCC3/MRP3 and reuptake is via the SLCO1B1/OATP1B1 and SLCO1B3/OATP1B3
carriers (12). Since the expression of OATP1B1 and OATP1B3 is higher in downstream
hepatocytes (hepatocytes located near the central vein), it is postulated that this reuptake
protects upstream hepatocytes (those located near the portal tracts) from saturating their
biliary secretory capacity (9,13).
Figure 1 summarizes the transporters and enzymes involved in hepatic uptake, conjugation,
secretion, and reuptake of bilirubin
Developmental Regulation of Transporters and Enzymes Involved in Bilirubin Clearance
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All components of hepatic clearance of bilirubin are developmentally regulated and
newborns have significantly reduced expression and/or activity of the transporters and
enzymes involved in uptake, conjugation, and excretion of bilirubin. SLCO1B1/OATP1B1
and SLCO1B3/OATP1B3 mRNA expression is approximately 500-fold lower in neonates
and 100-fold lower in infants up to the 12 months of age than in adults (14). GST has
multiple classes, with proteins belonging to class alpha (GST-A) having the highest affinity
to bilirubin (15). GST-A protein expression is 1.5 to 4-fold lower in newborns and reach
adult levels after the first 1–2 years of life (16). UGT1A1 enzyme activity is absent from
fetal livers, and is triggered in newborns by parturition (17). However, newborn UGT1A1
enzyme activity remains less than 1% of adult activity, and does not reach adult activity until
3 months of age (18). Hepatic ABCC2/MRP2 mRNA expression is 200-fold lower in
neonates and 100-fold lower in infants up to 12 months of age than in adults (14). Given the
reduced ability of the liver for bilirubin uptake, conjugation, and excretion, newborns are
particularly susceptible to developing hyperbilirubinemia, which can improve as enzyme
activities and liver function mature.

Inherited Disorders of Bilirubin Clearance
Inherited disorders involving defects in each of the four steps of hepatic bilirubin clearance
have been described. Many of these disorders present in the newborn period and range in
presentation from clinically insignificant to neurologically devastating and lethal.
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Disorders of bilirubin uptake and intrahepatic storage are only infrequently described in the
literature (19), and the clinical significance of these disorders remains to be confirmed.
Recent studies have demonstrated polymorphisms in GST genes that are associated with
increased risk of neonatal hyperbilirubinemia (15,20). The most important polymorphism
associated with neonatal hyperbilirubinemia is one that encodes for a partial gene deletion in
the GST mu (GST-M) gene class. This GSTM1 null mutation results in complete absence of
GSTM1 enzyme activity. Also, as noted above, polymorphisms in SLCO1B1/OATP1B1 and
SLCO1B3/OATP1B3 may modestly contribute to unconjugated hyperbilirubinemia (7,8).
Disorders of Conjugation

Author Manuscript

Inherited disorders of conjugation are primarily due to alterations in the UGT1A1 gene,
resulting in decreased or absent enzyme expression and function.
UGT Gene—The UGT gene is a superfamily of genes that encode enzymes catalyzing
glucuronidation of various substrates to facilitate their excretion (21). The gene that governs
bilirubin conjugation, UGT1 was cloned by Ritter et al in 1991 (22) and is located on
chromosome 2, at 2q37 (23). This gene consists of four common exons (exons 2, 3, 4, and 5)
and 13 unique promoter and first exons (variable exons) (Figure 2). A single variable first
exon and its promoter are spliced to the four common exons prior to transcription. Of the 13
possible genes that can be encoded, only that containing the variable exon A1 is involved in
bilirubin conjugation (13).
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UGT1A1 is the only enzyme catalyzing the generation of water-soluble bilirubin
glucuronides in hepatocytes, thus mutations in this gene lead to deficiencies in bilirubin
conjugation and excretion. To date, 130 UGT1A1 mutations, in both coding and non-coding
regions of the gene, have been identified that decrease or abrogate enzymatic function (24).
Conversely, UGT1A1 activity can be increased by phenobarbital administration, which
induces UGT1A1 gene expression by activating the distal phenobarbital response enhancer
element (25).
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Gilbert syndrome (GS)—First described in 1901 by Gilbert and Lereboulet (26), GS is
the most common hereditary hyperbilirubinemia syndrome, occurring in 3–13% of the
population (27,28). It is typically associated with at least 50% decrease in hepatic bilirubin
UGT activity (29). GS is now regarded as an autosomal recessive disorder, with affected
patients being either homozygotes or compound heterozygotes (i.e. two different recessive
alleles at a particular locus) (30). More than 100 different mutations have been implicated in
GS and their frequencies differ among different ethnic groups (31). The most common
genotype among Caucasians with GS is the homozygous polymorphism of two extra bases
(TA) in the TATAA box sequence of the promoter region of the UGT1A1 gene, resulting in a
sequence of A(TA)7TAA (also known as UGT1A1*28) instead of the normal
A(TA)6TAA(32,33). The extra TA repeat lessens the affinity of TATAA-binding protein to
the TATAA box, resulting in decreased gene expression. This A(TA)7TAA variant is highly
prevalent in the Western population, with an allelic frequency of 0.4 ((30,34). Various other
mutations, including missense mutations in the coding region are more prevalent in non-

Pediatr Res. Author manuscript; available in PMC 2016 April 05.

Memon et al.

Page 5

Author Manuscript

Western populations. For example, in East Asians from Japan, Korea, and China, GS most
commonly results from the Gly71Arg mutation (G71R; UGT1A1*6) in exon 1 (35). The
allelic frequency of the G71R mutation in this population is 0.16–0.21 (36,37), whereas the
A(TA)7TAA allelic frequency is only 0.11–0.15 (36).
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Clinical manifestation: Although GS is an inherited disorder, it typically first presents as
mild, intermittent unconjugated hyperbilirubinemia in otherwise asymptomatic young adults
without evidence of hemolysis or liver injury. GS can present in the newborn period,
especially if there is concurrent hemolytic disease such as ABO incompatibility or
glucose-6-phophatate dehydrogenase (G6PD) deficiency (38). Such infants are at high risk
for developing severe hyperbilirubinemia and even kernicterus. GS can also contribute to
neonatal hyperbilirubinemia in the absence of hemolytic disease as several authors have
shown that the A(TA)7TAA homozygous genotype is associated with higher serum bilirubin
levels, when compared to heterozygous and wild type controls (39–41). However, the
clinical significance of this finding remains unclear as the infants in these studies had either
subclinical or only mild/moderate hyperbilirubinemia (27). GS has also been associated with
the jaundice of inadequate breastfeeding with weight loss (“breastfeeding jaundice”) (42,43)
and with breast milk jaundice (see Breast milk jaundice) (44,45).
Diagnosis and management: In older children and adults, the diagnosis of GS can be made
by administering intravenous nicotinic acid (niacin) or oral rifampin and monitoring the
subsequent rise in bilirubin concentrations (46). Liver biopsy is not indicated and is usually
normal. Genetic testing can be useful in the work-up of prolonged neonatal jaundice, with
genotyping of the A(TA)7TAA variant in non-Asians and Gly71Arg mutation analysis in
Asian patients.
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Crigler-Najjar syndrome type I (CN syndrome type I)—In 1952, Crigler and Najjar
(47) described the most lethal form of hereditary hyperbilirubinemia, CN syndrome type I,
which is characterized by absent or nearly absent UGT1A1 enzyme activity (48). CN
syndromes are inherited in an autosomal recessive manner and patients are homozygotes or
compound heterozygotes. Mutations in CN syndrome type I are deleterious and consist of
either premature truncation or deletion of key amino acid sequences on any of the five exons
of the UGT1A1 gene (24). Additionally, intronic mutations resulting in frameshifts and
premature stop codons have been described (49). The majority of the mutations found in CN
syndrome type I are found in the common exons 2–5 and thus affect many UGT1 enzymes
(50).
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Clinical manifestation: CN syndrome type I presents shortly after birth with serum
bilirubin levels greater than 20 to 50 mg/dL. Consequently, it is associated with bilirubin
encephalopathy and death unless managed by aggressive phototherapy and exchange
transfusions in the immediate newborn period (51). The risk for kernicterus persists into
adult life (52).
Diagnosis and management: There is currently no simple test to confirm the diagnosis of
CN syndrome type I. Definitive diagnosis is by gene analysis and sequencing the coding
region for known mutations. Management in the newborn period consists of aggressive
Pediatr Res. Author manuscript; available in PMC 2016 April 05.
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phototherapy and exchange transfusions to keep bilirubin levels below the threshold for
kernicterus. Phototherapy for 8–12 hours daily is continued throughout the early years of
life, though its effectiveness decreases with time (53). The nonsense or stop codons that
cause CN syndrome type I preclude the use of phenobarbital to upregulate gene expression
(54). Liver transplantation remains the only definitive treatment for this disease (55). Gene
therapy may be a promising therapeutic option for these patients in the near future (56).
Crigler-Najjar syndrome type II (CN syndrome type II, aka Arias syndrome)—
Described by Arias in 1962 (57), CN syndrome type II is characterized by reduced (but not
abolished) UGT1A1 enzyme activity (< 10% of normal) (58). Unlike CN syndrome type I,
which is caused by various types of deleterious mutations, the genetic defect in CN
syndrome type II is usually a point mutation, causing a substitution of a single amino acid
residue, thereby reducing but not eliminating enzyme activity (24).
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Clinical manifestation: Unconjugated hyperbilirubinemia occurs in the first days of life,
but total bilirubin levels usually do not exceed 20 mg/dL (51). CN syndrome type II rarely
results in kernicterus. In older children and adults, illness and stress may cause temporary
increases in bilirubin levels.
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Diagnosis and management: CN syndrome type II can be clinically distinguished from CN
syndrome type I by lower levels of bilirubin (usually less than 20 mg/dL) and a decrease in
serum bilirubin levels by more than 30% after treatment with phenobarbital (58). Analysis of
bile pigments for bilirubin conjugates can also differentiate the two CN syndromes, with
only trace amounts of conjugated bilirubin present in type I and significant amounts of
monoconjugated bilirubin present in type II (59). Treatment includes aggressive
phototherapy in the newborn period and occasionally phenobarbital therapy. These patients
generally have a good prognosis.
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Are GS and CN syndrome type I ends of a continuous spectrum?—Historically
GS, CN syndrome type I, and CN syndrome type II have been characterized as distinct
clinical syndromes, distinguished by the degree of unconjugated hyperbilirubinemia.
However, intermediate phenotypes have been well described, suggesting that there is a
continuous spectrum of altered bilirubin conjugation (60,61). Due to the high frequency of
the Gilbert-type promoter in the general population (up to 40% of the Western population
has at least one Gilbert type allele), heterozygous carriers of mutations that cause CN
syndromes can also carry the Gilbert-type promoter on their normal allele, resulting in
compound heterozygosity and intermediate levels of hyperbilirubinemia. Therefore, the
variability of the UGT1A1 gene locus most likely leads to a continuous spectrum of altered
bilirubin conjugation, with GS and CN syndrome type 1 representing the two ends of the
spectrum (31).
Lucey-Driscoll syndrome (aka Transient Familial Neonatal Hyperbilirubinemia)
—In 1960, Lucey et al. (62) described a rare familial disorder that caused severe
unconjugated hyperbilirubinemia is the first few days of life. In vitro testing demonstrated
that sera of affected infants and their mothers contained an unidentified inhibitor of
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UGT1A1 activity. Since its original description in 1960, additional cases of Lucey-Driscoll
syndrome have not been reported in the literature and its existence has been questioned.
Clinical manifestation: Based on the original description, this syndrome presents with
severe hyperbilirubinemia in the immediate newborn period and can result in kernicterus and
death. Children who survive the neonatal period have no recurrence of hyperbilirubinemia
(62).
Diagnosis and management: The serum inhibitory effects gradually decline after delivery
and therefore this is a self-resolving condition. However, given the risk of severe
hyperbilirubinemia, these infants need to be monitored closely in the first two weeks of life
and may need treatment with aggressive phototherapy and possibly exchange transfusion if
threshold bilirubin levels are reached.
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Breast milk jaundice—First described by Newman and Gross in 1963 (63), breast milk
jaundice refers to a common and relatively benign cause of unconjugated hyperbilirubinemia
in healthy newborns who are primarily breastfed. Its etiology remains unknown, and several
components of breast milk such as pregnane-3β,20α-diol (pregnanediol) (64), other steroids
(cortisol and estriol), nonesterified fatty acids (65), β-glucoronidase (66), and epidermal
growth factor (67) have been implicated in its pathogenesis. Interestingly, polymorphic
mutations of UGT1A1 (especially mutations seen in GS) are associated with breast milk
jaundice. Specifically, studies in East Asian infants have shown a causal relationship
between infants with breast milk jaundice and the G71R mutation (36,45). A recent in vitro
study using transfected HepG2 cells demonstrated that pregnanediol did not alter UGT1A1
transcriptional and enzyme activity in wild-type or A(TA)7TAA variant expression vectors,
but reduced enzyme activity in G71R variant vectors by 51% (68). These studies suggest
that breast milk jaundice is caused by a combination of genetic and environmental factors
(i.e. breast milk components).
Clinical manifestations: Breast milk jaundice develops after 4–7 days of life and can
persist for as long as 3–4 months before spontaneous resolution. It is distinguished from
“breastfeeding jaundice”, which occurs with mild dehydration and weight loss in the first
few days of life because of insufficient intake or production of breast milk. Infants with
breast milk jaundice are otherwise healthy, with normal weight gain, normal stool and urine
output, and a normal physical examination. Total serum bilirubin levels usually do not
exceed 12 mg/dL (69), though higher bilirubin levels and rare cases of kernicterus have been
reported (70).
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Diagnosis and management: Discontinuation of breast milk and substitution with formula
results in rapid improvement in hyperbilirubinemia, which is both a diagnostic and
therapeutic option for breast milk jaundice. However, since breast milk jaundice is a benign
and self-limiting condition, current recommendations do not support discontinuation of
breastfeeding in these infants (69).
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Dubin-Johnson syndrome (DJS)—DJS was first described in 1954 by Dubin et al and
Sprinz et al who reported several cases of healthy young adults with chronic low-grade
jaundice (mostly conjugated hyperbilirubinemia) and black livers, with no other features of
hepatobiliary disease (71,72). It is an autosomal recessive disorder and genomic studies have
shown that DJS results from homozygous or compound heterozygous mutations in ABCC2/
MRP2 resulting in either absent or deficient expression of this transporter (73). Several
different mutations have been described in DJS patients, including exon skipping, missense,
nonsense and base deletion. Most mutations result in stop codons and failure of MRP2
transcription. Less frequently, they can result in endoplasmic reticulum retention of MRP2
and failure of translocation to the canalicular membrane (9).
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Clinical manifestation: DJS usually presents in young adulthood with predominantly
conjugated hyperbilirubinemia and otherwise normal liver studies. The conjugated
hyperbilirubinemia is mild because of urinary excretion of bilirubin glucuronides. Most
patients are asymptomatic except for occasional abdominal pain (13). There is no risk of
fibrosis or cirrhosis. Rarely, DJS can present in the neonatal period. Neonatal DJS differs
from adult-onset DJS in that it presents with severe cholestasis and hepatomegaly. Bilirubin
levels can reach > 20 mg/dL. Increased severity in neonates has been attributed to immature
bile physiology combined with the MRP2 defect. As the liver matures, infants become
asymptomatic until later in life, when they can present with intermittent hyperbilirubinemia
(74).
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Diagnosis and management: DJS in a benign disease and in adolescents and adults it does
not require treatment. Diagnosis, however, is important to eliminate the possibility of other
hepatobiliary disorders that may lead to hepatic injury. In addition to elevated conjugated
bilirubin levels in the setting of normal liver function tests, urine tests are diagnostic. Urine
tests reveal normal total coproporphyrin levels but the characterization of the coproporphyrin
reveals 80% coproporphyrin I in affected individuals, compared to 75% coproporphyrin III
in healthy controls (31). Coproporphyrin I is a metabolic byproduct of heme synthesis and
also an endogenous substrate of MRP2; therefore serum and urinary levels are increased in
the presence of defective MRP2 (73). Hepatobiliary iminodiacetic acid (HIDA) scan will
show either normal or slightly delayed visualization of the liver, with absent or delayed
gallbladder filling (75). Liver histology, though not necessary in establishing the diagnosis,
characteristically shows the presence of dark lysosomal melanin-like pigment deposits (12).
Genotyping of ABCC2 gene is possible, but typically not part of the routine clinical work up
(31).
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DJS should be suspected in any neonate with unexplained prolonged moderate to severe
conjugated hyperbilirubinemia. Similar to adults, diagnosis is made by elevated urine
coproporphyrin I levels. Computerized tomography (CT) of the abdomen can also be done
and will show attenuation of the liver (75). Therefore, characterization of urinary
coproporphyrins and abdominal CT should confirm the diagnosis without additional invasive
means. Given the significant cholestasis that occurs in this age group, treatment with
phenobarbital and ursodeoxycholic acid is recommended (74).
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Rotor syndrome (RS)—RS was first described by Rotor et al in 1948 and was initially
considered a variant of DJS (76). Subsequently, a number of functional studies confirmed
that patients with RS do not have defective biliary excretion, but rather a defect in hepatic
uptake and storage. RS is an autosomal recessive disorder. Animal experiments and studies
of patients with RS suggest that there are homozygous mutations of both SLCO1B1/
OATP1B1 and SLCO1B3/OATP1B3 resulting in simultaneous absence of OATP1B1 and
OATP1B3 transporters (12). Of note, SLCO1B1 and SLCO1B3 lie very close together on
chromosome 12.
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Clinical manifestation: Clinically, the disorder is indistinguishable from DJS, and presents
with predominantly a mixed conjugated and unconjugated hyperbilirubinemia in otherwise
asymptomatic individuals. It can present in the neonatal period or in childhood. Serum total
bilirubin levels are usually between 2 and 5 mg/dL, but can be higher.
Diagnosis and management: RS is benign and does not require any therapy. Again,
diagnosis is important to differentiate from other causes of hepatobiliary disorders. Urine
tests are diagnostic and can differentiate RS from DJS. In RS, total coproporphyrin excretion
in urine is elevated 2–5 fold, with 65% constituting coproporphyrin I (31). Further
diagnostic or invasive testing is usually not indicated. If performed, a HIDA scan will reveal
slow liver uptake and prominent kidney excretion (12) and histology will show normal liver
tissue with absent pigment (9).
The main characteristics of these disorders are summarized in Table 1 and the defective
transporters/enzymes are shown in Figure 3.
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Summary
Inherited disorders of bilirubin clearance can present with either unconjugated or conjugated
hyperbilirubinemia in the newborn period. Understanding the molecular basis and clinical
presentation of these syndromes is critical for differentiating those that are benign from
those that can be lethal and associated with kernicterus.
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Figure 1.

Schematic view of transporters and enzymes involved in hepatic bilirubin clearance. (Alb,
albumin; BCRP, breast cancer resistance protein; BMG, bilirubin monoglucuronide; BDG,
bilirubin diglucuronide; GST, glutathione-S-transferase; MRP, multidrug resistanceassociated protein; OATP, organic anion transport protein; UCB, unconjugated bilirubin;
UGT, uridine diphosphate glucuronosyl transferase).
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Figure 2.

Schematic representation of the UGT1 gene locus and the UGT1A1 protein. (Chr,
chromosome; PR, promoter regions; UGT, uridine diphosphate glucuronosyl transferase).
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Figure 3.

Schematic view of transporters and enzymes involved in inherited disorders of bilirubin
clearance. (Alb, albumin; BCRP, breast cancer resistance protein; BMG, bilirubin
monoglucuronide; BDG, bilirubin diglucuronide; CN, Crigler-Najjar; DJS, Dubin-Johnson
syndrome; GS, Gilbert syndrome; GST, glutathione-S-transferase; MRP, multidrug
resistance-associated protein; OATP, organic anion transport protein; RS, Rotor syndrome;
UCB, unconjugated bilirubin; UGT, uridine diphosphate glucuronosyl transferase).
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